Registration - Organization

Novartis Pharmaceuticals Canada Inc. / Mark Vineis, Canada Country President

Registration Information

Organization name: Novartis Pharmaceuticals Canada Inc.
Senior Officer Name: Mark Vineis, Canada Country President
Senior Officer Change History
Initial registration start date: 2010-05-04
Registration status: Active
Projected end date: No date provided
Registration number: 10154-2301

Associated Lobbying Activity Reports

Total number of Lobbying Activity Reports: 13

Lobbying Activity Reports - last 6 months: 0

Version 35 of 38 (2023-09-22 to 2023-10-01)

Registration versions:

Version 35 of 38 (2023-09-22 to 2023-10-01)

Lobbying Information

Subject Matter of the Lobbying Activities

Details Regarding the Identified Subject Matter

Will any of the lobbyists listed within this registration arrange a meeting between a public office holder and any other individual for the purpose of attempting to influence any of the matters listed below:

Yes

Specific Topics of Lobbying Communications	Intended Outcomes	Associated Subject Matters
CC on an email message to department staff regarding Health Canada Approval of an important new therapy.	Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health
Deliver a 'pipeline review' presentation to provide Pharmacare program management with details of products currently under development (or not yet available in Canada) for which Pharmaceutical, Laboratory & Blood Services Division (PLBSD) will be making future funding decisions.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health, Hospitals, Senior Citizens
Deliver a 'pipeline review' presentation to provide Pharmacare program management with details of products currently under development (or not yet available in Canada) for which Pharmaceutical Services Division will be making future funding decisions.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health, Hospitals
Discussions with BC government officials/organizations and elected representatives to obtain public reimbursement of Novartis' innovative pharmaceutical treatments for BC citizens that require publicly funded access to these treatments, through various BC government programs such as Pharmacare, Health Authorities, BC Cancer Agency, etc. And, to encourage the BC government to recognize the importance of Novartis investments in Research and Development to the development of BC's healthcare bioscience research ecosystem and to providing innovative approaches to management of the health care system.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health, Hospitals, Science and Technology, Senior Citizens
Discussions with BC government officials/organizations and elected representatives to obtain public reimbursement of Novartis' innovative treatments for BC citizens that require access to these treatments, through various BC government funded programs such as Pharmacare, Health Authorities, BC Cancer Agency, etc. And, to encourage the BC government to recognize the importance of Novartis investments in Research and Development to the development of BC's healthcare bioscience research ecosystem and to providing innovative approaches to management of the health care system.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Economic Development and Trade, Health, Hospitals
Meeting request to explore and understand BC Ministry of Health challenges, barriers, timelines and possible solutions to enable patients to be treated with innovative specialized therapies at sites in BC. (BC patients currently do not have access or are traveling to out-of-province jurisdictions to receive some innovative therapies.)	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health
Meetings with government officials regarding government funding to facilitate patient access to Novartis pharmaceutical treatments	Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health
Meeting with the Minister of Jobs, Economic Development and Innovation to discuss the BC Life Sciences Strategy and Novartis' role as a key partner in the province's bioscience ecosystem, including data partnerships, patient access to innovative medicines and expanded access to diagnostic equipment.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Economic Development and Trade, Health, Science and Technology
Request a meeting to discuss innovative program pioneered by the NHS (England) to address cardiovascular disease risk factor mitigation through a collaborative program created to identify and treat patients high risk for CVD due to elevated cholesterol levels that does not meet current Clinical Guideline standards as published by the Canadian Cardiovascular Congress. Enacting such a program in BC will impact health system resource use caused by the downstream impact of Cardiovascular disease; heart attack, stroke, etc.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health, Hospitals, Senior Citizens

BC Ministries/Provincial Entities

Fraser Health Authority
Health
Innovate BC
Jobs, Economic Development and Innovation
Member(s) of the BC Legislative Assembly
Office of the Premier
Providence Health Care Society
Provincial Health Services Authority
Vancouver Coastal Health Authority
Vancouver Island Health Authority

Organization Details

Senior Officer Name and Position during the Period of this Registration

Andrea Marazzi, Novartis Country President Canada

Organization Contact Information

Novartis Pharmaceuticals Canada Inc.

Address:
700 St-Hubert Street, Suite 100
Montreal, QC H2Y 0C1
Canada

Telephone number: 780-288-1286

Description of Activities

Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative medicines and procedures to improve the health and well-being of Canadians. Novartis is a leading investor in pharmaceutical research and development worldwide and in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 900 people and has been named multiple times as one of the "50 Best Employers in Canada". For further information, please visit www.novartis.ca.

Gifts or benefits provided by the organization

Gifts or Benefits Provided to Public Officer Holders
Name	Gift or Benefit Description	Circumstance	Date Promised	Value Promised	Date Given	Value Given
No Records

Contributors to the Lobbying Activity

No person or organization contributed over $1000CDN, within the preceding 12 months, toward the lobbying activity on behalf of the organization that has a direct interest in the outcome of the lobbying activity.

Government Funding in the Last 12 Months

No government funding was requested or received within the preceding 12 months.

Coalition Members Information

Innovative Medicines Canada
- 55 Metcalfe Street
  Suite 1220
  Ottawa, ON K1P 6L5
  Canada
Life Sciences BC
- 1066 West Hastings Street
  Suite 1890
  Vancouver, BC V6E 3X2
  Canada

Affiliates with a Direct Interest in the Outcome

Sandoz Canada Inc.
- 110 de Lauzon
  Boucherville, QC J4B 1E6
  Canada

Other Persons or Organizations with Direct Interests

The activities of Novartis Pharmaceuticals Canada Inc. are not controlled or directed by another person or organization with a direct interest in the outcome of this undertaking.

Lobbyists Details

Lobbyists Employed by this Organization

Lobbyist

Contributions

Graham Anderson
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No

Lobbied a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization on or after 2020-09-21 and before 2024-09-21: No

Caroline Barber
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No

Lobbied a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization on or after 2020-09-21 and before 2024-09-21: Yes

Political: No
Sponsorship: No
Recall: No

Jeremy Chorney
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No

Lobbied a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization on or after 2020-09-21 and before 2024-09-21: Yes

Political: No
Sponsorship: No
Recall: No

Thea Discepola
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No

Lobbied a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization on or after 2020-09-21 and before 2024-09-21: Yes

Political: No
Sponsorship: No
Recall: No

Clayton Gilmore
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No

Lobbied a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization on or after 2020-09-21 and before 2024-09-21: No

Andrea Marazzi
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No

Lobbied a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization on or after 2020-09-21 and before 2024-09-21: Yes

Political: No
Sponsorship: No
Recall: No

Jordan Roumieu
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No

Lobbied a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization on or after 2020-09-21 and before 2024-09-21: No

Novartis Pharmaceuticals Canada Inc.

Name change history

Name change history
Name	From	To
Novartis Pharmaceuticals Canada Inc.	2010-05-04	current

Novartis Pharmaceuticals Canada Inc.

Senior Officer History
Senior Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Mark Vineis	2024-01-01	Current
Pedro Ferreira	2023-10-01	2024-01-01
Andrea Marazzi	2022-06-01	2023-10-01
Christian Macher	2020-03-17	2022-06-01
Geoffrey Squires	2010-05-04	2020-02-26

Mark Vineis, Canada Country President (Organization)

Learn more...

Designated Filers are required to submit a Lobbying Activity Report for each lobbying activity with a senior public officer holder. The name of the most senior paid officer (i.e. the designated filer) will appear on all in-house Lobbying Activity Reports, whether or not he/she participated in the activity.

Note: Lobbying Activity Reports are due on the 15^th day of each month for lobbying activities that took place in the previous month.

Results below are sorted by posted date, beginning with the most recent.

Results 1-13 of 13

Novartis Pharmaceuticals Canada Inc.
Organization

Senior Public Office Holders who were lobbied in this activity:
- Brenda Bailey, Minister of Jobs, Economic Development and Innovation | Jobs, Economic Development and Innovation
- Paul Pawlowski, Assistant Deputy Minister, Investment Division | Jobs, Economic Development and Innovation
- Nina Cagic, Director, Internal Trade and Investment Operations | Jobs, Economic Development and Innovation
Lobbying Activity date: 2023-06-22
Lobbyists who performed the lobbying activity: Andrea Marazzi, Caroline Barber, Jeremy Chorney
Posted date: 2023-09-22
Lobbying Activity number: 2301-28945 View Lobbying Activity Report
Novartis Pharmaceuticals Canada Inc.
Organization

Senior Public Office Holders who were lobbied in this activity:
- Brenda Bailey, Minister of Jobs, Economic Development and Innovation | Jobs, Economic Development and Innovation
- Terry Harrison, Chief of Staff | Jobs, Economic Development and Innovation
- Paul Pawlowski, Assistant Deputy Minister, Investment Division | Jobs, Economic Development and Innovation
Lobbying Activity date: 2023-06-05
Lobbyists who performed the lobbying activity: Andrea Marazzi, Caroline Barber, Jeremy Chorney
Posted date: 2023-09-22
Lobbying Activity number: 2301-28944 View Lobbying Activity Report
Novartis Pharmaceuticals Canada Inc.
Organization

Senior Public Office Holders who were lobbied in this activity:
- Ian Rongve, Assistant Deputy Minister, Innovation | Health
Lobbying Activity date: 2022-09-22
Lobbyists who performed the lobbying activity: Geoffrey Squires
Posted date: 2022-10-14
Lobbying Activity number: 2301-21439 View Lobbying Activity Report
Novartis Pharmaceuticals Canada Inc.
Organization

Senior Public Office Holders who were lobbied in this activity:
- Maureen O'Donnel, Associate Deputy Minister | Health
Lobbying Activity date: 2022-06-17
Lobbyists who performed the lobbying activity: Geoffrey Squires
Posted date: 2022-07-14
Lobbying Activity number: 2301-19855 View Lobbying Activity Report
Novartis Pharmaceuticals Canada Inc.
Organization

Senior Public Office Holders who were lobbied in this activity:
- Mitch Moneo, Assistant Deputy Minister | Health
Lobbying Activity date: 2022-05-13
Lobbyists who performed the lobbying activity: Geoffrey Squires
Posted date: 2022-06-14
Lobbying Activity number: 2301-19167 (amended from 2301-19165) View Lobbying Activity Report
Novartis Pharmaceuticals Canada Inc.
Organization

Senior Public Office Holders who were lobbied in this activity:
- Mitch Moneo, Assistant Deputy Minister | Health
Lobbying Activity date: 2022-05-06
Lobbyists who performed the lobbying activity: Geoffrey Squires
Posted date: 2022-05-09
Lobbying Activity number: 2301-18076 View Lobbying Activity Report
Novartis Pharmaceuticals Canada Inc.
Organization

Senior Public Office Holders who were lobbied in this activity:
- Mitch Moneo, Assistant Deputy Minister | Health
Lobbying Activity date: 2022-03-18
Lobbyists who performed the lobbying activity: Collette Williams
Posted date: 2022-04-14
Lobbying Activity number: 2301-17770 View Lobbying Activity Report
Novartis Pharmaceuticals Canada Inc.
Organization

Senior Public Office Holders who were lobbied in this activity:
- Mitch Moneo, Assistant Deputy Minister | Health
Lobbying Activity date: 2021-07-02
Lobbyists who performed the lobbying activity: Geoffrey Squires, Kimberly King
Posted date: 2021-07-13
Lobbying Activity number: 2301-10877 View Lobbying Activity Report
Novartis Pharmaceuticals Canada Inc.
Organization

Senior Public Office Holders who were lobbied in this activity:
- Mitch Moneo, Assistant Deputy Minister | Health
Lobbying Activity date: 2021-06-10
Lobbyists who performed the lobbying activity: Collette Williams, Sophie Rochon
Posted date: 2021-07-15
Lobbying Activity number: 2301-10876 View Lobbying Activity Report
Novartis Pharmaceuticals Canada Inc.
Organization

Senior Public Office Holders who were lobbied in this activity:
- Mitch Moneo, ADM | Health
Lobbying Activity date: 2020-12-16
Lobbyists who performed the lobbying activity: Geoffrey Squires
Posted date: 2021-01-15
Lobbying Activity number: 2301-5330 View Lobbying Activity Report
Novartis Pharmaceuticals Canada Inc.
Organization

Senior Public Office Holders who were lobbied in this activity:
- John Horgan, Premier | Member(s) of the BC Legislative Assembly
- Adrian Dix, Minister of Health | Member(s) of the BC Legislative Assembly
Lobbying Activity date: 2020-11-20
Lobbyists who performed the lobbying activity: Andrea Marazzi, Christian Macher, Geoffrey Squires
Posted date: 2020-12-11
Lobbying Activity number: 2301-4345 View Lobbying Activity Report
Novartis Pharmaceuticals Canada Inc.
Organization

Senior Public Office Holders who were lobbied in this activity:
- Mitch Moneo, Assistant Deputy Minister | Health
Lobbying Activity date: 2020-07-14
Lobbyists who performed the lobbying activity: Thea Discepola
Posted date: 2020-08-14
Lobbying Activity number: 2301-1728 View Lobbying Activity Report
Novartis Pharmaceuticals Canada Inc.
Organization

Senior Public Office Holders who were lobbied in this activity:
- Mitch Moneo, Assistant Deputy Minister | Health
Lobbying Activity date: 2020-07-02
Lobbyists who performed the lobbying activity: Geoffrey Squires
Posted date: 2020-07-08
Lobbying Activity number: 2301-403 View Lobbying Activity Report

Date Modified:: 2024-11-13

Menus

www.lobbyistsregistrar.bc.ca

Registration - Organization

Novartis Pharmaceuticals Canada Inc. / Mark Vineis, Canada Country President

Registration Information

Associated Lobbying Activity Reports

Version 35 of 38 (2023-09-22 to 2023-10-01)

Version 35 of 38 (2023-09-22 to 2023-10-01)

Details Regarding the Identified Subject Matter

BC Ministries/Provincial Entities

Senior Officer Name and Position during the Period of this Registration

Organization Contact Information

Description of Activities

Gifts or benefits provided by the organization

Contributors to the Lobbying Activity

Government Funding in the Last 12 Months

Coalition Members Information

Affiliates with a Direct Interest in the Outcome

Other Persons or Organizations with Direct Interests